SEC Comment Letter 0000000000-24-005955 to Structure Therapeutics Inc. (GPCR) (CIK 0001888886) (GPCR)
Structure Therapeutics Inc. (GPCR) (CIK 0001888886)
Date: May 22, 2024 · CIK: 0001888886 · Accession: 0000000000-24-005955
AI Filing Summary & Sentiment
File numbers found in text: 001-41608
Letter
United States securities and exchange commission logo May 22, 2024 Jun Yoon Chief Financial Officer Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, California Re:Structure Therapeutics Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-41608 Dear Jun Yoon: We have reviewed your filings and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Annual Report on Form 10-K Risk Factors Risks Related to Our Reliance on Third Parties We rely on third parties for the manufacture of our product candidates for preclinical and clinical development . . . , page 82 1.We note your disclosure that “certain Chinese biotechnology companies and CMOs may become subject to trade restrictions, sanctions, and other regulatory requirements by the U.S. government, which could restrict or even prohibit [y]our ability to work with such entities[.]” In future filings, please expand this disclosure by including a discussion of pending legislation and/or other methods that would result in trade restrictions, sanctions, or other regulatory requirements by the U.S. government, which could restrict or even prohibit your ability to work with such entities. Please also discuss whether any pending legislation and/or other methods would result in sanctions or other regulatory actions could restrict or even prohibit your ability to utilize your subsidiary's research and development operations office in China. To the extent you are unable to replace such supply agreements or contract manufacturing agreements, please consider whether you are
FirstName LastNameJun Yoon Comapany NameStructure Therapeutics Inc. May 22, 2024 Page 2 FirstName LastName Jun Yoon Structure Therapeutics Inc. May 22, 2024 Page 2 substantially dependent on it and it is required to be filed pursuant to Item 601(b)(10)(ii)(B) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gary Newberry at 202-551-3761 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Doris Stacey Gama at 202-551-3188 or Joshua Gorsky at 202-551-7836 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 22, 2024
Jun Yoon
Chief Financial Officer
Structure Therapeutics Inc.
601 Gateway Blvd., Suite 900
South San Francisco, California
94080
Re:Structure Therapeutics Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-41608
Dear Jun Yoon:
We have reviewed your filings and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Annual Report on Form 10-K
Risk Factors
Risks Related to Our Reliance on Third Parties
We rely on third parties for the manufacture of our product candidates for preclinical and clinical
development . . . , page 82
1.We note your disclosure that “certain Chinese biotechnology companies and CMOs may
become subject to trade restrictions, sanctions, and other regulatory requirements by the
U.S. government, which could restrict or even prohibit [y]our ability to work with such
entities[.]” In future filings, please expand this disclosure by including a discussion of
pending legislation and/or other methods that would result in trade restrictions, sanctions,
or other regulatory requirements by the U.S. government, which could restrict or even
prohibit your ability to work with such entities. Please also discuss whether any pending
legislation and/or other methods would result in sanctions or other regulatory actions
could restrict or even prohibit your ability to utilize your subsidiary's research and
development operations office in China. To the extent you are unable to replace such
supply agreements or contract manufacturing agreements, please consider whether you are
FirstName LastNameJun Yoon
Comapany NameStructure Therapeutics Inc.
May 22, 2024 Page 2
FirstName LastName
Jun Yoon
Structure Therapeutics Inc.
May 22, 2024
Page 2
substantially dependent on it and it is required to be filed pursuant to Item
601(b)(10)(ii)(B) of Regulation S-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Gary Newberry at 202-551-3761 or Lynn Dicker at 202-551-3616 if you
have questions regarding comments on the financial statements and related matters. Please
contact Doris Stacey Gama at 202-551-3188 or Joshua Gorsky at 202-551-7836 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences